Core Viewpoint - Tonghua Pharmaceutical (300636) has completed technical upgrades at its first factory, leading to increased production capacity and reduced unit costs, which helps mitigate the impact of exchange rate fluctuations and depreciation pressure, thereby enhancing gross margins [1] Group 1: Production and Cost Management - The completion of technical upgrades at the company's first factory has resulted in an increase in production capacity [1] - The company has achieved a reduction in unit costs due to these upgrades [1] - These improvements are expected to effectively counterbalance the pressures from exchange rate fluctuations and depreciation [1] Group 2: Supply Chain Strategy - The company is diversifying its raw material procurement by certifying and sourcing from more than three suppliers across different provinces [1] - This strategy aims to mitigate risks associated with reliance on a single region or supplier, ensuring supply chain security [1]